Pridinol

from Wikipedia, the free encyclopedia
Structural formula
Structural formula of pridinol
General
Non-proprietary name Pridinol
other names
  • 3- ( N -piperidinyl) -1,1-diphenyl-1-propanol methanesulfonate
  • 3-piperidino-1,1-diphenylpropanol
  • 3-piperidinyl-1,1-diphenylpropan-1-ol
Molecular formula C 20 H 25 NO
External identifiers / databases
CAS number
EC number 208-128-0
ECHA InfoCard 100.007.390
PubChem 4904
ChemSpider 4735
DrugBank DB13642
Wikidata Q827515
Drug information
ATC code

M03 BX03

Drug class

Muscle relaxants

properties
Molar mass 295.42 g mol −1
Physical state

firmly

safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances

Pridinol mesilate

07 - Warning

Caution

H and P phrases H: 332-312-302
P: 261-264-280-301 + 312-302 + 352-304 + 340
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Pridinol is a centrally acting muscle relaxant with an anticholinergic mechanism of action. The muscle-relaxing effect of Pridinol is said to take place via the inhibition of polysynaptic reflexes . The exact mechanism of action is still unclear.

The active ingredient is used medicinally as pridinol mesilate , i.e. the salt of methanesulfonic acid , and is available in tablet form and as an injection solution.

application areas

The drug is approved for the treatment of muscle spasms, lower back pain , torticollis (wry neck) and general muscle pain in adults.

Side effects

Occasionally (≥1 / 1000, <1/100) a. Side effects such as restlessness, dizziness, nausea, stomach pain, dry mouth, fatigue occur. Rare (≥ 1 / 10,000, <1 / 1,000) side effects may include a. Hypersensitivity reactions, impaired attention, coordination or taste, and impaired vision.

Interactions

Pridinol increases the effects of anticholinergics such as atropine .

Pharmacodynamics

The pharmacological effect is mediated via an atropine-like mechanism that attacks the smooth muscles of the organs as well as the striated skeletal muscles . This means that central and peripheral tension in the skeletal muscles can be treated. Central states of tension ( spasticity ) are always caused by damage in the central nervous system (CNS), while peripheral tension has its cause outside the CNS and z. B. triggered by lack of exercise or poor posture.

Pharmacokinetics

The maximum blood concentration is reached about 1 hour after ingestion. Most of the drug is excreted within 24 hours, partly in unchanged form, partly as glucuronate and as sulfoconjugate via the kidneys .

Trade names

Myditin (D), Myopridin (D), Lyseen (I)

Pridinol tablets were directly on the market in Germany from 1998 to 2016 as Myoson . New approvals were granted in December 2017 ( myopridin ) and December 2018 ( myditin ).

Web links

Individual evidence

  1. ↑ a b Entry on Pridinol Methanesulfonate Salt at Toronto Research Chemicals , accessed on May 6, 2020 ( PDF ).
  2. ^ Forth W., Henschler D. et al .: General and special pharmacology and toxicology (6th edition, 1992).
  3. ↑ External identifiers or database links for pridinol mesilate : CAS number: 6856-31-1, EC number: 229-953-2, ECHA InfoCard: 100.027.230 , PubChem : 165542 , ChemSpider : 145082 , Wikidata : Q27274059 .
  4. ↑ a b c Technical information Myditin 3 mg tablets (Trommsdorff), as of August 2019.
  5. ↑ 50 years of drug telegram. Still not optimal - studies and approval decisions , arznei-telegramm (at) 2019.
  6. ↑ curtain on pridinol , pharmacy adhoc, February 28 2018th